Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 04/06/25
End: 12/31/30
Due: 12/31/31
Phase: N/A
Priority: Normal
Start: 04/24/19
End: 09/02/21
Due: 09/02/22
Phase: N/A
Priority: Normal
Start: 03/08/17
End: 07/08/21
Due: 07/08/22
Phase: N/A
Priority: Normal
Start: 07/07/17
End: 04/30/21
Due: 04/30/22
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age | NCT05766839 | Vifor Pharma, Inc. | user2@example.com | None | 2025-04-06 | 2030-12-31 | 2031-12-31 | - | - | 2025-07-14 |
| Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND) | NCT03888066 | Vifor Pharma, Inc. | user2@example.com | None | 2019-04-24 | 2021-09-02 | 2022-09-02 | - | - | 2025-07-14 |
| FDDA Utilization Study (FDDAU) | NCT05861492 | Vifor Pharma, Inc. | user2@example.com | None | 2017-03-08 | 2021-07-08 | 2022-07-08 | - | - | 2025-07-14 |
| Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia | NCT03087058 | Vifor Pharma, Inc. | user2@example.com | None | 2017-07-07 | 2021-04-30 | 2022-04-30 | - | - | 2025-07-14 |